| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 19046 |
| Drug | Avelumab |
| Brand | Bavencio® |
| Indication | Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 29/10/2019 |
| Rapid review completed | 02/01/2020 |
| Rapid review outcome | Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. |
| Full pharmacoeconomic assessment commissioned by HSE | 07/01/2020 |
| Pre-submission consultation with Applicant | 18/02/2020 |
| Full submission received from Applicant | 31/07/2020 |
| Preliminary review sent to Applicant | 02/02/2021 |
| NCPE assessment re-commenced | 09/03/2021 |
| Follow-up to preliminary review sent to Applicant | 24/03/2021 |
| NCPE assessment re-commenced | 14/04/2021 |
| Factual accuracy sent to Applicant | 28/05/2021 |
| NCPE assessment re-commenced | 04/06/2021 |
| NCPE assessment completed | 23/06/2021 |
| NCPE assessment outcome | The NCPE recommends that avelumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013
